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The pathway by which the chordates
evolved from lower animal groups
remains elusive [1,2]. Recently,
molecular evidence has shed light on
the problem, suggesting that
chordates share a common body plan
with articulates (arthropods and
annelids); that notoneuralian
chordates may have inverted their
dorsoventral body axis while evolving
from a gastroneuralian ancestor [3,4];
and that insect and vertebrate brains
and nerve cords are built according to
a common ground plan [5]. Here, we
propose that enteropneusts (acorn
worms, hemichordata), a putative
sister group of the chordates, may
link invertebrates with
dorsoventrally inverted chordates,
and that their ventral trunk cord may
correspond to the nerve cords of both
articulates and chordates. 
Enteropneusts have in their trunk
region a dorsal and a ventral
concentration of nerve cells that both
converge anteriorly into the dorsal
collar cord (Fig. 1). In the collar cord,
the epidermis and associated nerve
cells form a tube that has been
compared to the dorsal neural tube in
chordates [6]. Interestingly, giant
nerve cells that reside in the dorsal
collar cord project their giant fibres,
via a prebranchial circumenteric
nerve ring, into the ventral — and not
into the dorsal — trunk cord [7,8],
and the ventral trunk cord is about
twice as thick as its dorsal counterpart
[6,7]. In line with this, severing the
dorsal trunk cord does not prevent
the animal’s retreat response to an
anterior stimulus, whereas a cut
across the ventral trunk cord does [7].
It thus appears that the enteropneust
dorsal collar cord plus ventral trunk
cord form the system controlling
locomotor patterns, as do the ventral
nerve cord in articulates and the
dorsal nerve cord in chordates. 
The only spontaneously active
nervous centre in enteropneusts —
their putative brain — is contained in
the proboscis [7]. Hence, in
enteropneusts, a ventral nerve cord is
connected, via a circumenteric nerve
ring, to the dorsoanterior brain, as is
the case in gastroneuralian articulates
(Fig. 1). Assuming that articulate and
chordate nerve cords and brains
represent homologous structures
[3,5], the same homology could hold
for the enteropneust brain plus
ventral nerve cord. If this is the case,
then the conventional ventral side of
enteropneusts should correspond to
the dorsal side of chordates. This is in
contrast to the current view [2,9–11].
Interestingly, various additional
features appear also to be
dorsoventrally interchanged between
conventionally oriented
enteropneusts and chordates: for
example, the hepatic structures and
the direction of blood flow (Fig. 1).
Another example is the ventral
pygochord in enteropneusts
(vacuolated cells in the posteroventral
mesentery [9–11]) as compared to the
dorsal notochord in chordates (Fig. 1).
And, interestingly, an ortholog of the
chordate Brachyury gene (required for
notochord formation [12]) is also
expressed in the posteroventral
mesoderm of gastroneuralian insects
[13] — in a location corresponding to
the posteroventral pygochord in
enteropneusts.
One major problem is evident. In
chordates, the mouth opens — given
their dorsoventral inversion — to
their former dorsal side (Fig. 1). We
have suggested that the chordate
mouth is a new mouth, with the old
mouth having been obliterated [3–5].
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Figure 1
Comparison of the generalized body plans of
an annelid, an enteropneust and a chordate,
with the chordate turned upside down. The
direction of blood flow (arrows) and the
relative positions of the gut (green), the
principal nerve cord (yellow) and the chordate
notochord and enteropneust pygochord
(brown) are the same. Similarly, the paired
hepatic outpockets in the enteropneust lie in a
region comparable to the typhlosole (t) in the
annelid and to the liver in the chordate (dark
green). Note that the proposed homology
between the enteropneust stomochord (s)
and the chordate notochord [14] has been
contested repeatedly [2,10,11]. The
arrowhead indicates the position of the mouth
in the putative gastroneuralian ancestor of
chordates; note that the functional mouth of
the chordate is a new mouth (see [3,4]).
Additional abbreviations: cc, collar cord; col,
collar; pro, proboscis; p, pygochord; trk, trunk. 
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In accordance with this
interpretation, the anlage of the
enteropneust and chordate mouths
map to opposite sides of the brain
rudiment [2], with the anlage of the
enteropneust mouth corresponding
to the proposed location of the
obliterated mouth in chordates [3–5].
So, if one equates the
conventional ventral side of
enteropneusts with the dorsal side of
the chordates, then in both body
plans the brain plus (principal) nerve
cord, as well as the pygochord or
notochord, the direction of blood flow
and the hepatic structures coincide
(Fig. 1). In the future, expression
patterns of orthologous genes should
help to assess the hypothesis that
enteropneusts conceptually link the
articulate and chordate body plans,
provided that we compare the ventral
side of enteropneusts with the dorsal
side of chordates.
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Gazetteer
Biogen, Inc.
What is it famous for? Being one of
the first biotechnology companies, and
the oldest one still to be independent.
How did it start? It was founded in
1978 by an international group of
scientific luminaries, including
Phillip Sharp, Kenneth Murray and
Walter Gilbert. Sharp is currently
chairman of the scientific board.
Does it actually sell any products?
Not yet. Like most biotechnology
firms, Biogen started out by licensing
its most promising products to larger
firms in return for royalties on sales.
Interferon-a was licensed to
Schering-Plough, and recombinant
hepatitis B antigens, used for
vaccines, were licensed to SmithKline
Beecham and to Merck. But Biogen
should soon start to market a product
of its very own, interferon-b1A.
What is interferon-b1A good for?  In
December 1995, an advisory
committee recommended the US
Federal Drug Agency approve its use
as a treatment for relapsing forms of
multiple sclerosis (MS). In a Phase III
trial, treatment with the drug reduced
the progression of patients with MS by
40 % — by an unknown mechanism. 
What else is it working on? Most of
the products in preclinical or early
clinical development are immuno-
suppressants: for example, an
antibody to VLA-4 which should stop
lymphocyte traffic through blood
vessel walls, and an engineered
antibody-like molecule that seems to
inhibit T-cell proliferation.
Does the company make a profit?
Usually. In 1993, it made a profit of
$32.4 million, in 1994 a loss of
$4.9 million, and in 1995 a profit
again, to the tune of $5.6 million. The
main reason for the loss in 1994 was a
cost of $25 million for stopping work
on Hirulog, a leech-derived thrombin
inhibitor, after a Phase III trial
showed that it was no better than
heparin at preventing clot formation. 
Where do the profits go?  Some are
reinvested, some go to individuals,
and some are funnelled into the
academic community. For example,
royalties paid to Kenneth Murray for
work on hepatitis B have been
donated to Edinburgh University
and the Darwin Trust, providing
funds for a new library, a biological
sciences building, graduate students
and postdoctoral fellows.  
How does it compare with other
biotechnology companies? As a profit-
making company, however erratic,
Biogen probably rates as one of the
top five biotechnology companies. At
around 500 employees, it doesn’t
compare in size with Amgen or
Genentech, but there aren’t many
other larger biotech companies.
How much does it put into research?
In 1995, Biogen’s total revenues were
$151.7 million, of which $87.4 million
was spent on research and
development. R & D staff number
186; Biogen currently employs 88
PhDs and MDs in total. The
expectation of new revenues from
interferon-b1A sales has triggered a
hiring frenzy in all parts of the
company; jobs on offer can be found
on Biogen’s web site (http://www.
careermosaic.com/cm/biogen/).
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